SPDR® S&P International HealthC Sect ETF
Johnson & Johnson’s Valuation Cheat Sheet
On January 26, 2017, the company was trading at a forward PE of ~15.8x. Based on the last five years’ multiple range, JNJ’s current valuation is neither high nor low.
Why the Majority of Analysts Deem Novartis a ‘Buy’
Novartis met Wall Street analysts’ estimates for EPS (earnings per share) in 4Q16, reporting EPS of $1.12 as estimated but missing revenue estimates.
Quarterly Performance of GlaxoSmithKline’s Global Pharmaceuticals
GlaxoSmithKline’s (GSK) immuno-inflammation franchise, which includes Benlysta, reported a rise of 9.0% in revenues at constant exchange rates to 93.0 million pounds in 2Q17 compared to 2Q16.
Novartis’s Valuation after 1Q17 Earnings
On April 27, 2017, Novartis was trading at a forward PE multiple of ~15.8x. The industry currently trades at a forward PE multiple of ~15.9x.
Performance of GlaxoSmithKline’s HIV Business in 2016
HIV products reported growth of 37% to ~3.6 million pounds in 2016 compared to 2015.
How GlaxoSmithKline’s Valuation Compares to Its Peers’
According to data released on December 28, 2016, GlaxoSmithKline’s stock has fallen ~5.1% over the last 12 months. What do analysts expect for the next 12 months?
Roche’s Oncology Wheelhouse Stacked with Competitive Drugs
Headquartered in Basel, Switzerland, Roche (RHHBY) is a leading pharmaceutical company. Roche’s Pharmaceuticals and Diagnostics businesses comprise more than 77% and ~22.5%, respectively, of the company’s total revenues.